Pharming Group (OTCMKTS:PHGUF) Reaches New 1-Year High - What's Next?

Key Points

• Pharming Group's share price reached a new 52-week high of $1.19 during mid-day trading, closing at $1.16 with a trading volume of 4,000 shares.
• The company maintains a debt-to-equity ratio of 0.51, indicating a relatively low level of debt compared to its equity.
• Pharming Group specializes in developing and commercializing protein replacement therapies for rare diseases, with products like RUCONEST and Joenja available in various markets.

Pharming Group NV (OTCMKTS:PHGUF - )'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $1.19 and last traded at $1.16, with a volume of 4000 shares changing hands. The stock had previously closed at $1.16.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.76 and a quick ratio of 2.00. The stock's 50-day moving average is $1.15 and its 200 day moving average is $1.00.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.